FB-418 is under clinical development by 1St Bio Therapeutics and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FB-418’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FB-418 is under development for the treatment of Parkinson’s disease and amyotrophic lateral sclerosis (ALS). The therapeutic candidate acts by targeting leucine-rich repeat kinase 2 (LRRK2) and c Abl protein. It is administered through oral route.
1St Bio Therapeutics overview
1st Bio Therapeutics (1st Bio) is a healthcare company that provide treatment for degenerative brain diseases. The company is headquartered in Seongnam-si, Gyeonggi-do, South Korea.
For a complete picture of FB-418’s drug-specific PTSR and LoA scores, buy the report here.